Transaction overview
Infinite Epigenetics, a U.S.-based biotechnology company focused on epigenetic diagnostics and personalized health interventions, acquired Tally Health, also a U.S.-based firm specializing in epigenetic age testing for consumers. The acquisition was finalized on December 14, 2023, with the announcement made on April 29, 2026. Although the financial details of the deal remain undisclosed, the transaction aims to consolidate Infinite Epigenetics' position as a leader in epigenetic data analysis and product development by integrating Tally Health's extensive DNA methylation dataset and personalized health recommendations into its existing operations.
Deal structure and financing
The specific equity and debt composition for this acquisition is not disclosed. L Catterton served as the lead financial advisor to Infinite Epigenetics on this transaction, while sell-side advisors remain undisclosed at the time of writing. Tally Health’s DNA methylation dataset, which includes data from 8,000 participants, is considered a key asset in the deal. The integration aims to create vertical synergy across testing and supplementary products, with a focus on leveraging Infinite Epigenetics' established research capabilities for further product development and validation. No information is available regarding seller retained stakes or lock-up provisions; however, there are no indications of IPO optionality as part of this transaction.
Strategic context
Infinite Epigenetics sought Tally Health to expand its epigenetic data platform and accelerate the integration of personalized health recommendations into market offerings. This acquisition complements Infinite Epigenetics' existing subsidiary TruDiagnostic's focus on research, academia, payers, and providers by adding a direct consumer engagement component through Tally Health’s services. Tally Health, founded in 2023, has developed a business model that leverages epigenetic age testing based on cheek swab samples to provide personalized health interventions and supplements tailored to individual needs. The combined dataset will enable both companies to enhance product development and validation processes, positioning them at the forefront of innovative healthcare solutions.
Regulatory path
The acquisition by Infinite Epigenetics did not trigger a regulatory review from U.S. antitrust authorities such as the Federal Trade Commission (FTC) or the Department of Justice (DOJ), given the nature of the deal's specifics and the limited overlap in their respective markets. No remedies were required, and there are no publicly available details regarding Hart-Scott-Rodino filings or other regulatory submissions. Given Tally Health’s primary operations within the United States, it is unlikely that this transaction involved cross-border regulatory scrutiny from foreign jurisdictions such as the European Union (EU) or others, although Infinite Epigenetics may need to comply with local regulations in specific markets where they operate internationally.